Fibrosing rheumatic diseases (scleroderma, MCTD, IgG4-related disease, scleroderma mimics)
Michael Brenner, MD
Brigham and Women's Hospital, Harvard Medical School
Newton, MA, United States
Disclosure(s): 4FO Ventures: Consultant (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing); Mestag Therapeutics: Consultant (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Third Rock Ventures: Consultant (Ongoing)
Robert Lafyatis, MD
University of Pittsburgh
Pittsburgh, PA, United States
Disclosure(s): Advarra/GSK: Advisor or Review Panel Member (Ongoing); Bain Capital: Consultant (Terminated, September 22, 2023); Boehringer-Ingelheim: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); Certa Therapeutics: Consultant (Ongoing); Corbus: Consultant (Terminated, August 1, 2022), Grant/Research Support (Terminated, August 1, 2022); EMD Serono: Consultant (Ongoing); Formation: Consultant (Terminated, July 1, 2022), Grant/Research Support (Terminated, July 1, 2022); Genentech: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Merck/MSD: Consultant (Ongoing); Moderna: Grant/Research Support (Terminated, January 1, 2023); Morphic: Consultant (Ongoing); Pfizer: Consultant (Terminated, April 6, 2023), Grant/Research Support (Terminated, April 6, 2023); Regeneron: Grant/Research Support (Terminated, January 1, 2023); Third Rock Venture: Consultant (Ongoing); Thirona Bio: Consultant (Ongoing), Officer or Board Member (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Zag Bio: Consultant (Ongoing)
Michael Longaker, MD, MBA
Stanford
Atherton, CA, United States
Disclosure(s): No financial relationships with ineligible companies to disclose
Fibroblasts are key cells in a variety of homeostatic and pathologic processes, including inflammatory arthritis and fibrosis of the lung, kidney, skin, and heart, all of which cause significant morbidity and mortality in rheumatologic patients. Recent work has defined novel subsets of fibroblasts, new functional roles for fibroblasts, and new paradigms for how fibroblasts perform normally, which may allow treatment of conditions previously thought to be irreversible.
Speaker: Robert Lafyatis, MD – University of Pittsburgh
Speaker: Michael Brenner, MD – Brigham and Women's Hospital, Harvard Medical School
Speaker: Michael Longaker, MD, MBA – Stanford